Market LIVE
Published markets; coverage varies by country
Product profile · United States

ANNOVERA

 ·  Patent Litigation & Settlement History ↓

IngredientETHINYL ESTRADIOL; SEGESTERONE ACETATE
Application typeNDA
Application209627
Product001
Dosage formRING
RouteVAGINAL
Strength0.013MG/24HR;0.15MG/24HR
Approval date2018-08-10
Marketing statusPrescription
Status event—
ApplicantMAYNE PHARMA
Product source

Current GenericRadar decision

Year2023
SelectionDEEP_REVIEW
ReviewFINAL_CHECKING
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2023-08-10
Patent anchor—
Exclusivity anchor2023-08-10
Protection date—
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2023. Anchor type: REGULATORY_EXCLUSIVITY. Patent anchor: not recorded. Exclusivity anchor: 2023-08-10. Anchor date: 2023-08-10. Patent tail: yes. Exclusivity tail: no. Review status: FINAL_CHECKING. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
106320662039-02-01U U-2787———
———
106320662039-02-01U U-2786———
———
107656282039-02-01U U-2786———
———
107656282039-02-01U U-2787———
———
107800472039-02-01U U-2786———
———
107800472039-02-01U U-2787———
———
109186492039-06-21DP ————
———
109258822039-06-21DP ————
———
109401572039-06-21DP ————
———
115293082039-06-21DP ————
———
118502512039-06-21U U-3785———
———
123035182039-06-21DP ————
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE—2023-08-10FDA historical NCE 5-year new chemical entity exclusivity. Active-moiety-wide protection against covered follow-on NDA/ANDA applications; not indication-specific. Statutory exceptions or waivers are not excluded by this categorization.YY——Source

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.